U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

Substance Class Structurally Diverse
Created
by admin
on Sat Dec 16 13:26:46 UTC 2023
Edited
by admin
on Sat Dec 16 13:26:46 UTC 2023
Source Materials Class ORGANISM
Source Materials Type AUTOLOGOUS HUMAN
Source Materials State LIVE
Source Materials Parent
Part BLOOD
Fraction Material Type CELL
Fraction Name CD4 AND CD8 POSITIVE
Record UNII
U2I8T43Y7R
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
AXICABTAGENE CILOLEUCEL
USAN  
INN   USAN  
Official Name English
Axicabtagene ciloleucel [WHO-DD]
Common Name English
axicabtagene ciloleucel [INN]
Common Name English
YESCARTA
Brand Name English
AUTOLOGOUS T CELLS TRANSDUCED WITH RETROVIRAL VECTOR ENCODING AN ANTI-CD-19 CD28/CD3-ZETA CHIMERIC ANTIGEN RECEPTOR
Common Name English
AXICABTAGENE CILOLEUCEL [USAN]
Common Name English
Cells are derived from isolated blood of the patient and are transduced with non-replicative retroviral vector encoding the FMC63 anti-CD19 single chain variable fragment (scFv) CD28/CD3zeta chimeric antigen receptor (FMC63-28Z CAR). Cells exhibit anti-t
Common Name English
KTE-C19
Code English
Axicabtagene ciloleucel (autologous CD19 CAR transduced PBL)
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C129826
Created by admin on Sat Dec 16 13:26:46 UTC 2023 , Edited by admin on Sat Dec 16 13:26:46 UTC 2023
FDA ORPHAN DRUG 515615
Created by admin on Sat Dec 16 13:26:46 UTC 2023 , Edited by admin on Sat Dec 16 13:26:46 UTC 2023
FDA ORPHAN DRUG 735920
Created by admin on Sat Dec 16 13:26:46 UTC 2023 , Edited by admin on Sat Dec 16 13:26:46 UTC 2023
NCI_THESAURUS C28681
Created by admin on Sat Dec 16 13:26:46 UTC 2023 , Edited by admin on Sat Dec 16 13:26:46 UTC 2023
FDA ORPHAN DRUG 423914
Created by admin on Sat Dec 16 13:26:46 UTC 2023 , Edited by admin on Sat Dec 16 13:26:46 UTC 2023
FDA ORPHAN DRUG 515915
Created by admin on Sat Dec 16 13:26:46 UTC 2023 , Edited by admin on Sat Dec 16 13:26:46 UTC 2023
FDA ORPHAN DRUG 740320
Created by admin on Sat Dec 16 13:26:46 UTC 2023 , Edited by admin on Sat Dec 16 13:26:46 UTC 2023
NCI_THESAURUS C137999
Created by admin on Sat Dec 16 13:26:46 UTC 2023 , Edited by admin on Sat Dec 16 13:26:46 UTC 2023
EU-Orphan Drug EU/3/15/1553
Created by admin on Sat Dec 16 13:26:46 UTC 2023 , Edited by admin on Sat Dec 16 13:26:46 UTC 2023
Code System Code Type Description
USAN
DE-33
Created by admin on Sat Dec 16 13:26:46 UTC 2023 , Edited by admin on Sat Dec 16 13:26:46 UTC 2023
PRIMARY
DRUG BANK
DB13915
Created by admin on Sat Dec 16 13:26:46 UTC 2023 , Edited by admin on Sat Dec 16 13:26:46 UTC 2023
PRIMARY
RXCUI
1987398
Created by admin on Sat Dec 16 13:26:46 UTC 2023 , Edited by admin on Sat Dec 16 13:26:46 UTC 2023
PRIMARY
DAILYMED
U2I8T43Y7R
Created by admin on Sat Dec 16 13:26:46 UTC 2023 , Edited by admin on Sat Dec 16 13:26:46 UTC 2023
PRIMARY
NCI_THESAURUS
C120309
Created by admin on Sat Dec 16 13:26:46 UTC 2023 , Edited by admin on Sat Dec 16 13:26:46 UTC 2023
PRIMARY
INN
10518
Created by admin on Sat Dec 16 13:26:46 UTC 2023 , Edited by admin on Sat Dec 16 13:26:46 UTC 2023
PRIMARY
FDA UNII
U2I8T43Y7R
Created by admin on Sat Dec 16 13:26:46 UTC 2023 , Edited by admin on Sat Dec 16 13:26:46 UTC 2023
PRIMARY
Related Record Type Details
ACTIVE MOIETY

Agent Modifications

Modification Process Modification Role Modification Type Amount Fragment Name Fragment ID
CULTURE ACTIVATOR IMMUNOLOGICAL MUROMONAB-CD3 JGA39ICE2V
CULTURE GROWTH FACTOR BIOLOGICAL ALDESLEUKIN M89N0Q7EQR
TRANSDUCTION ANTIGEN EXPRESSION TRANSDUCING VECTOR UNSPECIFIED SUBSTANCE 0f2235db

Structural Modifications

Modification Type Location Site Location Type Residue Modified Extent Fragment Name Fragment Approval
MOIETY ANTI-CD-19 CD28/CD3-ZETA CHIMERIC ANTIGEN RECEPTOR (KTE-CD19) V248BS56D0